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1222 © 2019 The British Pharmacological SocBackground and Purpose: A new class of dihydropyridine derivatives, which act as
co‐inducers of heat shock protein but are devoid of calcium channel antagonist and
vasodilator effects, has recently been developed with the purpose of selectively
targeting neurodegeneration. Here, we evaluated the action of one of these novel
compounds LA1011 on neurovascular coupling in the ischaemic rat cerebral cortex.
As a reference, we applied nimodipine, a vasodilator dihydropyridine and well‐
known calcium channel antagonist.
Experimental Approach: Rats were treated with LA1011 or nimodipine, either by
chronic, systemic (LA1011), or acute, local administration (LA1011 and nimodipine).
In the latter treatment group, global forebrain ischaemia was induced in half of the
animals by bilateral common carotid artery occlusion under isoflurane anaesthesia.
Functional hyperaemia in the somatosensory cortex was created by mechanical stim-
ulation of the contralateral whisker pad under α‐chloralose anaesthesia. Spreading
depolarization (SD) events were elicited subsequently by 1 M KCl. Local field poten-
tial and cerebral blood flow (CBF) in the parietal somatosensory cortex were moni-
tored by electrophysiology and laser Doppler flowmetry.
Key Results: LA1011 did not alter CBF, but intensified SD, presumably indicating
the co‐induction of heat shock proteins, and, perhaps an anti‐inflammatory effect.
Nimodipine attenuated evoked potentials and SD. In addition to the elevation of
baseline CBF, nimodipine augmented hyperaemia in response to both somatosensory
stimulation and SD, particularly under ischaemia.
Conclusions and implications: In contrast to the CBF improvement achieved with
nimodipine, LA1011 seems not to have discernible cerebrovascular effects but may
up‐regulate the stress response.common carotid arteries (“two‐vessel occlusion”); CBF, cerebral blood flow; DC, direct current; EFP, evoked field potential; eNOS,
oppler flowmetry; LFP, local field potential; MABP, mean arterial BP; rSD, recurrent spreading depolarization; SD, spreading
train of events
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What is already known
• LA1011, a dihydropyridine derivative and co‐inducer of
heat shock protein, is neuroprotective in models of
chronic neurodegeneration.
• Nimodipine, a dihydropyridine derivative and L‐type
voltage‐gated Ca2+ channel antagonist, decreases
resting vascular tone.
What this study adds
• LA1011 has no major effect on the cerebrovascular
system but intensifies spreading depolarization, possibly
by modulating potassium currents.
• Nimodipine effectively improves neurovascular coupling,
particularly under cerebral ischaemia.
What is the clinical significance
• LA1011 may be considered to counteract
neurodegeneration, with no concomitant impact on
vascular tone.
SZABÓ ET AL. 1223BJP1 | INTRODUCTION
Treatment with the dihydropyridine compound nimodipine (isopropyl
2‐methoxyethyl 1,4‐dihydro‐2,6‐dimethyl‐4‐(3‐nitrophenyl)‐3,5‐pyri-
dinedicarboxylate) has long been recommended in clinical practice to
alleviate neurological symptoms of acute or chronic cerebrovascular
diseases, such as subarachnoid haemorrhage or vascular dementia
(Tomassoni, Lanari, Silvestrelli, Traini, & Amenta, 2008). Nimodipine
has proven to be particularly relevant for the treatment of cerebro-
vascular disorders, because it achieves vasorelaxation by inhibiting
calcium influx to vascular smooth muscle cells through L‐type
voltage gated calcium channels, and, in addition, it also exerts neu-
roprotection by preventing neuronal calcium overload (Scriabine,
Schuurman, & Traber, 1989). Although nimodipine was proposed to
increase cerebral blood flow (CBF) by its selective affinity to cerebral
arteries without altering systemic blood pressure (Freedman &
Waters, 1987), the approved dose can still initiate undesired
side effects (Kieninger et al., 2017) including hypotension in
some patients (Diringer & Zazulia, 2017; Porchet, Chioléro, & de
Tribolet, 1995).
Recently, a new class of dihydropyridine derivatives devoid of
vasodilator and anti‐hypertensive action has been developed with
the purpose of selectively targeting neurodegeneration (Fülöp et al.,
2013; Kasza et al., 2016). One of these promising novel compounds
is LA1011 (dimethyl 4‐(4‐trifluoromethylphenyl)‐2,6‐bis‐(2‐dimethy-
laminoethyl)‐1‐methyl‐1,4‐dihydropyridine‐3,5‐dicarboxylate dihydro-
chloride), which is known as a co‐inducer of heat shock protein (Hsp;
especially Hsp27 and Hsp70) with no affinity for calcium channels
(Kasza et al., 2016). Long‐term administration of LA1011 was shown
to improve learning ability, counteract neuronal loss, increase dendritic
spine density, and restrain tau pathology and amyloid plaque forma-
tion in a transgenic mouse model of Alzheimer's disease (Kasza et al.,
2016), possibly by maintaining protein homeostasis (Penke et al.,
2018). Taken that Hsp27 and Hsp70 activation has been suggested
to be protective against ischaemic neurodegeneration (Kim, Han,
Lee, & Yenari, 2018; van der Weerd et al., 2010; Yenari et al., 2005),
it is of interest whether LA1011, a co‐inducer of Hsp, has the potential
to preserve neuronal function under cerebral ischaemia. Hence, here,
we set out to assess the impact of LA1011 treatment on neuronal
activation in the acutely ischaemic rat cerebral cortex.
Cerebral ischaemia impairs neuronal function in part by
compromising neurovascular coupling (Jackman & Iadecola, 2015).
Neurovascular coupling is a vital feed‐forward control mechanism,
which adjusts local CBF to the energy requirements of activated
neurons (Attwell et al., 2010; Roy & Sherrington, 1890). Inefficient
neurovascular coupling therefore deprives neurons of their essential
nutrient supply and leads to failing neuronal function. Even though
the cerebrovascular action of nimodipine has been studied in much
detail, there is only indirect and ambiguous reference to its impact
on neurovascular coupling (Suzuki, Ooi, & Seki, 2012). More impor-
tantly, it is still not known whether LA1011 may achieve neuroprotec-
tion by improving neurovascular coupling. The second goal of this
study was, therefore, to assess the potentially beneficial action ofLA1011 and nimodipine on the efficacy of neurovascular coupling
during ischaemia and in the intact rat cerebral cortex.
As a final point, ischaemic brain injury gives rise to the spontane-
ous recurrence of spreading depolarization (SD), a wave of mass depo-
larization of neurons that propagates across the cerebral grey matter
at a rate of 2–6 mm·min−1 (Hossmann, 1996; Leão, 1944; Nedergaard,
1996; Somjen, 2001). SD elicited experimentally in the intact cerebral
cortex is known as an ischaemic preconditioning stimulus (Shen et al.,
2016). Furthermore, SDs spontaneously recurring in the injured
brain to exacerbate ischaemic brain injury and contribute to the
expansion of the primary lesion by affecting the associated CBF
response (Dreier, 2011; Hartings et al., 2017; Woitzik et al., 2013).
Limiting SD occurrence in patients has thus emerged as a therapeutic
approach to constrain ischaemia‐related, delayed neurological deficit
(Sakowitz et al., 2009). Furthermore, nimodipine has been demon-
strated to moderately impede SD (Richter, Ebersberger, & Schaible,
2002) and to convert the harmful vasoconstrictive CBF response to
SD into hyperaemia in an experimental model of subarachnoid haem-
orrhage (Dreier et al., 2002). In anticipation of identifying favourable
pharmacological effects, we investigated here the impact of LA1011
on SD occurrence and the development of the coupled CBF response,
with nimodipine used as a reference compound.
2 | METHODS
2.1 | Surgical procedures
Animal studies are reported in compliance with the ARRIVE guidelines
(Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the
recommendations made by the British Journal of Pharmacology. The
1224 SZABÓ ET AL.BJPexperimental procedures were approved by the National Food Chain
Safety and Animal Health Directorate of Csongrád County, Hungary.
The procedures were performed according to the guidelines of the
Scientific Committee of Animal Experimentation of the Hungarian
Academy of Sciences (updated Law and Regulations on Animal Protec-
tion: 40/2013. [II. 14.] Gov. of Hungary), following the EU Directive
2010/63/EU on the protection of animals used for scientific purposes.
Young adult, male Sprague–Dawley rats (Charles River Laborato-
ries, 323 ± 36 g, n = 62) were used in this study. Standard rodent chow
and tap water were supplied ad libitum. The animals were housed
under constant temperature, humidity, and lighting conditions (23°C,
12:12 hr light/dark cycle, lights on at 7 a.m.).
On the day of the experiments, animals were anaesthetized with
1.5–2% isoflurane in N2O:O2 (3:2) and were allowed to breathe spon-
taneously through a head cone during surgical interventions. Two
series of experiments were designed on the basis of pharmacological
treatment strategy (Figure 1; Table 1). In Series 1, isoflurane anaesthe-
sia was maintained throughout the experimental protocol. In Series 2,
isoflurane was substituted with α‐chloralose (dissolved in saline at a
concentration of 7 mg·ml−1 and administered either as a bolus injec-
tion of 40 mg·kg−1 per 15 min for initiation and 40 mg·kg−1·hr−1 for
maintenance, i.v., or as a bolus injection of 50 mg·kg−1 for initiation
and 30 mg·kg−1·hr−1 for maintenance, i.p.) for the period of actual data
acquisition. Body temperature was kept at 37.2°C by a feedbackTABLE 1 Physiological variables and number of animals included in each
Series
Pharmacological
treatment
Ischaemia
induction n
Body
weight (g)
Arterial
blood pH
Series 1 Vehicle Intact 6 342 ± 14 7.43 ± 0.0
LA1011 6 336 ± 23 7.40 ± 0.0
Series 2 Vehicle Intact 9 335 ± 32 7.33 ± 0.0
2VO 8 326 ± 48 7.33 ± 0.0
LA1011 Intact 6 310 ± 40 7.28 ± 0.0
2VO 9 305 ± 45 7.35 ± 0.0
Nimodipine Intact 6 331 ± 31 7.39 ± 0.0
2VO 6 313 ± 25 7.30 ± 0.0
Note: Data are given as mean ± stdev. 2VO, permanent, bilateral occlusion of t
blood pressure.controlled homeothermic blanket (Harvard Apparatus, Holliston, MA,
USA). In order to avoid the production of airway mucus, atropine
was administered (0.1%, 0.05 ml; i.m.) shortly before surgical proce-
dures. The mean arterial blood pressure (MABP) was continuously
monitored via a left femoral artery catheter. The adjacent femoral vein
was also cannulated for the administration of the anaesthetic agent,
whenever relevant.
For the later initiation of incomplete global forebrain ischaemia, a
midline incision was made in the neck, and both common carotid
arteries were carefully separated from the vagal nerves. Lidocaine
(1%) was administered topically before opening the skin and each tis-
sue layer underneath. A surgical thread used as occluder was looped
around each artery for later occlusion of the arteries. Control rats
(i.e., those with intact cerebral perfusion) were either sham operated
or naïve. All rats were placed prone in a stereotaxic apparatus
(Stoelting Co., Wood Dale, IL, USA). The skin above the skull and tem-
poral muscle were retracted from the underlying right parietal and
temporal bones. Two cranial windows (~3 × 3 mm) 1 mm apart were
prepared over the right parietal cortex (3 mm caudal from bregma
and 5 mm lateral from the sagittal suture). A high‐precision electrical
drill (Technobox, Bien Air 810; Switzerland) was used to thin the bone
under saline cooling, and the remaining soft bone layer was gently
peeled away to reveal the dura surface. The dura was then carefully
opened in each craniotomy. The rostral window was later used forFIGURE 1 Time lines of the protocols
implemented. 2VO: permanent, bilateral
occlusion of the common carotid arteries
(“two‐vessel occlusion”); Nimo: nimodipine;
rSD: recurrent spreading depolarization; SD:
spreading depolarization; SD1: first spreading
depolarization in a train of events
experimental group
Arterial pO2
(mmHg)
Arterial
pCO2
(mmHg)
MABP prior to
drug/vehicle
administration
(mmHg)
MABP after
drug/vehicle
administration
(mmHg)
4 123.7 ± 6.4 37.4 ± 12.0 N/A N/A
4 100.6 ± 18.3 36.5 ± 7.8 N/A N/A
7 140.5 ± 29.6 47.4 ± 11.4 92 ± 14 100 ± 22
3 127.0 ± 32.8 39.9 ± 6.3 100 ± 1 102 ± 8
2 127.8 ± 30.9 47.8 ± 5.7 102 ± 10 102 ± 12
5 117.8 ± 34.8 38.9 ± 8.6 93 ± 11 100 ± 22
6 103.4 ± 16.1 44.8 ± 8.1 103 ± 18 106 ± 15
5 99.8 ± 4.4 56.2 ± 11.2 89 ± 12 92 ± 15
he common carotid arteries (“two‐vessel occlusion”); MABP, mean arterial
SZABÓ ET AL. 1225BJPdata acquisition (i.e., electrophysiology and CBF measurement) and
topical drug administration, while the caudal window served SD elici-
tation. The cranial windows were constantly kept moist by artificial
cerebrospinal fluid (aCSF; mM concentrations: 126.6 NaCl, 3 KCl, 1.5
CaCl2, 1.2 MgCl2, 24.5 NaHCO3, 6.7 urea, 3.7 glucose bubbled with
95% O2 and 5% CO2 to achieve a constant pH of 7.4). Experiments
were terminated at the end of the experimental protocol by an over-
dose of the anaesthetic agent.
2.2 | Recording of electrophysiological variables
A saline‐filled glass capillary electrode (20 μm outer tip diameter) was
inserted 700 μm deep into the cerebral cortex at the rostral window
for the synchronous recording of local field potential (LFP) and slow
cortical or direct current (DC) potential. An Ag/AgCl reference
electrode was implanted under the skin of the animal's neck. The elec-
trophysiological signals were recorded via a high input impedance
pre‐amplifier (NL102GH, NeuroLog System, Digitimer Ltd., UK), con-
nected to a differential amplifier (NL106, NeuroLog System, Digitimer
Ltd.) with associated filter and conditioner systems (NL125, NL530,
NeuroLog System, Digitimer Ltd.). Potential line frequency noise
(50 Hz) was removed by a high‐quality noise eliminator (HumBug,
Quest Scientific Instruments Inc., Canada) without any signal attenua-
tion. Analogue to digital conversion was performed by a dedicated
A/D converter card (NI USB‐6008/6009, National Instruments,
Austin, TX, USA) controlled through a custom‐made software, written
in LabView (National Instruments; RRID:SCR_014325).
2.3 | Monitoring of local CBF
Laser Doppler flowmetry (LDF) was used to record changes in local
CBF in response to somatosensory (whisker) stimulation and SD. A
laser Doppler needle probe (Probe 403 connected to PeriFlux 5000;
Perimed AB, Sweden) was positioned above the barrel cortex, which
is supplied by arterial blood arriving via penetrating arterioles
branching off the pial arterioles carrying blood from the middle cere-
bral artery (Wu et al., 2016). The ideal position of the LDF probe
was identified prior to the actual experimental protocol: The probe
was positioned over the region where the amplitude of functional
hyperaemia in response to whisker stimulation proved to be the
greatest. The LDF signal was digitalized and acquired, together with
the DC potential and LFP, essentially as described above.
2.4 | Pharmacological treatment
Animals were assigned to pharmacological treatments randomly. In
Series 1, LA1011 (property of Gedeon Richter Plc., kindly provided
at the time of experimentation by LipidArt Ltd., Szeged, Hungary;
1 mg·kg−1 body weight in 0.4 ml saline) or its vehicle (i.e., saline) was
administered systemically (i.p.) in equal volume, twice a day for 2 weeks
before surgical intervention. In Series 2, the rostral cranial window was
incubated with either LA1011 (100 μM, in aCSF) or nimodipine
(Sigma‐Aldrich, 100 μM in 0.1% DMSO in aCSF) following a 5 min
baseline recording. Drug solutions were refreshed every 10 min tomaintain efficacy until the termination of each experiment. In other
rats, rinsing the cranial window with vehicle served as a control for
pharmacological treatments.2.5 | Experimental protocol
In Series 1, three SD events were triggered in each animal (n = 12) by
placing a 1 M KCl‐soaked cotton ball in the caudal craniotomy. The
cotton ball was removed, and the craniotomy was rinsed with aCSF
after each successful SD elicitation, to allow the development of a sin-
gle SD in response to each trigger. SDs were provoked at an inter‐SD
interval of at least 15 min (Figure 1).
In Series 2, after drug incubation for 30 min, both common carotid
arteries were permanently occluded (two‐vessel occlusion [2VO]) by
pulling on the occluder lines until resistance was felt and then securing
the occluders in place (n = 23). Successful 2VO was confirmed by a
sharp drop in the LDF signal. Rats with no occlusion served as control
for 2VO (i.e., intact, n = 21). Fifteen minutes after 2VO onset, whisker
stimulation involving the entire left whisker pad was performed
mechanically. Stimulation frequency was set at 2–3 Hz, each stimula-
tion lasting for 25 s. The stimulation was repeated 4 times with 2 min
intermissions. Subsequently, exactly as in Series 1, three SD events
were triggered by placing a 1 M KCl‐soaked cotton ball in the caudal
craniotomy. Considering the combination of 2VO and pharmacological
manipulations, eight experimental groups were established (Table 1).
The ischaemia model has been widely used (Farkas, Luiten, & Bari,
2007); rodents are the typical model organisms to study neurovascular
coupling or SD (Hartings et al., 2017; Iadecola, 2017). The experi-
menter was not blinded to the procedure, because she had to create
ischaemia by a surgical intervention (thus, it was clear which animal
was allocated to the ischaemic group).2.6 | Data analysis
All variables (i.e., DC potential, LDF signal, and MABP) were simulta-
neously acquired, displayed live, and stored using a personal computer
equipped with a custom‐made software in LabView (National Instru-
ments). Data analysis was assisted by the inbuilt instructions of the
software AcqKnowledge 4.2 for MP 150 (Biopac Systems, Inc., Goleta,
USA). Raw LDF recordings were downsampled to 1 Hz and then
expressed relative to baseline by using the average CBF value of the
first 5 min (100%) and the biological zero obtained after terminating
each experiment (0%) as reference points. Evoked field potentials
(EFPs) during whisker stimulation were analysed in the original LFP
recordings acquired at 2000 Hz, while raw DC recordings were also
downsampled to 1 Hz.
Blinding data analysis was intended by assigning codes to files and
recordings, which do not reveal the experimental condition (i.e., date
of the experiment). All recordings were first screened for events suit-
able for comprehensive analysis. For EFPs, it was required that the
segment under analysis (10 s) was completely free of harmonic net-
work oscillations (~50 Hz, produced by the feedback controlled on–
off switch of the heating blanket) or any accidental noise produced
1226 SZABÓ ET AL.BJPby manipulations by the experimenter. For SD analysis, it was essential
that an SD elicited propagated to the recording window. The evalua-
tion of CBF responses was achieved when hyperaemia evolved in
response to stimulation (functional hyperaemia in response to whisker
stimulation remained undetectable on several occasions, and SDs in
one animal gave rise to inverse neurovascular coupling) and if the
CBF responses to subsequent events were clearly separated.
In the case of whisker stimulation, the peak amplitude of evoked
potentials was assessed to reveal drug effect, if any. The efficacy of
hyperaemia was characterized by measuring the maximum amplitude
of the CBF response (mean of 15 s at the plateau of the hyperaemia).
For SD events, peak amplitude, duration at half amplitude, and the
rate of repolarization were measured on the DC potential trace. The
hyperaemic element of the CBF response was first sorted on the basis
of the presence of late hyperaemia. Type 1 was noted whenever peak
hyperaemia was obvious, but late hyperaemia remained undetectable.
The CBF response was labelled Type 2 when both peak and late
hyperaemia could be identified confidently. The SD‐associated
hyperaemia was then characterized by the peak amplitude, and the
duration of hyperaemia (peak and late elements together), taken from
deflection from and return to baseline. Data analysis was shared
among four independent investigators.
Unequal group sizes were achieved because some of the com-
pleted experiments did not qualify for comprehensive data analysis
due to high arterial blood pCO2 and low arterial blood pH values
(n = 4), unsuccessful SD elicitation (n = 1), or an overdose of anaesthe-
sia during the experimental protocol (n = 1). However, pilot
experiments, which met all the criteria of a successful experiment
(e.g., anaesthesia protocol yielding physiological arterial blood gas
values, uninterrupted monitoring of mean arterial pressure, appropri-
ate concentration of drug solutions, successful somatosensory stimu-
lation, and SD elicitation; n = 6), were incorporated in the final
groups to utilize all relevant data produced.
Data are given as mean ± stdev. The results were statistically
analysed with the software SPSS (IBM SPSS Statistics for Windows,Version 22.0, IBM Corp., USA; RRID:SCR_002865). The distribution
of the data was tested with the Shapiro–Wilk normality test. Outliers
were filtered with Grubbs test. Homogeneity of the variances was
checked by Levene's test. Two‐ or three‐way ANOVA models were
used, dependent on the type of data obtained. Levels of significance
were defined as *P < 0.05. Tukey's HSD or Games–Howell post hoc
test was used for group comparisons, whenever applicable. Non‐
parametric data were statistically evaluated with a Pearson chi‐square
test for association. All relevant statistical methods are given in each
figure legend. The data and statistical analysis comply with the recom-
mendations of the British Journal of Pharmacology on experimental
design and analysis in pharmacology.2.7 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Kelly
et al., 2017; Alexander, Striessnig et al., 2017).3 | RESULTS
3.1 | Physiological variables and baseline variations
of CBF
Physiological variables (MABP, arterial blood pH, and partial arterial
pressure of O2 and CO2) are presented in Table 1. Statistical analysis
did not reveal any significant ischaemia‐ or treatment‐related differ-
ence across experimental groups.
Typical, original recordings of the DC potential and CBF variations
over the full experimental protocol of Series 2 are shown in Figure 2.FIGURE 2 Representative direct current
(DC) potential and cerebral blood flow (CBF)
traces of the full experimental protocol
including common carotid artery occlusion
(2VO) in Series 2 under vehicle (upper box) or
nimodipine (lower box) treatment. The traces
were downsampled to 1‐Hz frequency
(original sampling frequency: 500 or 2000 Hz),
and the CBF traces were smoothed by median
filtering for 6 data points. Note that
nimodipine gradually elevated baseline
perfusion, increased the amplitude of
functional hyperaemia to whisker stimulation,
and enlarged hyperaemia in response to the
first (SD1) and recurrent spreading
depolarizations (rSD). Also, nimodipine
reduced SD amplitude. Note also the strikingly
different size of the CBF response to whisker
stimulation and SD within the same
preparation
FIGURE 3 Variation of baseline cerebral blood flow (CBF; i.e., inbetween stimulations) with respect to pharmacological treatments. (a) CBF prior
to the first experimental intervention (i.e., production of spreading depolarization [SD] in Series 1, or induction of ischaemia in Series 2). In Series 2,
the intact group and the group of animals later undergoing bilateral common carotid artery occlusion (2VO) are merged, because they received
identical handling until this point of the experimental protocol. (b) CBF before the production of the first SD (SD1). Data are expressed as change
with respect to the corresponding baseline. (c) CBF before the production of recurrent SD events (rSD). Data are given as mean ± stdev; sample
size (i.e., number of animals) is indicated in each bar. Statistical analysis relied on a two‐wayANOVA paradigm (factors: acute/chronic and treatment),
Panel (a), or a three‐way ANOVA (acute/chronic, ischaemia, and treatment), Panels (b) and (c). The level of significance was defined as *P < 0.05.
Tukey's HSD post hoc test was applied for group comparisons (*P < 0.05 vs. vehicle; #P < 0.05 vs. LA1011; $P < 0.05 vs. respective intact)
SZABÓ ET AL. 1227BJPVariation of baseline CBF was assessed at selected time points of
the experimental protocol, in order to evaluate the impact of phar-
macological treatments (Figure 3). Ischaemia induction in Series 2
obviously caused a marked reduction of CBF (53 ± 23%), which sta-
bilized in the vehicle‐treated group at 74 ± 11% prior to first SD
(SD1) and at 67 ± 15% prior to recurrent SDs (rSDs; Figure 3b,c).
The occurrence of SD produced long‐lasting oligaemia, the final
element of the CBF response to SD, which was apparent between
SD events in the intact groups, as well (Figure 3c). Neither chronic
nor acute treatment with LA1011 altered baseline CBF at any time
point or condition considered. In contrast, nimodipine treatment
increased baseline CBF significantly by the time of ischaemiaFIGURE 4 The impact of ischaemia or pharmacological treatments on e
during whisker stimulation in Series 2. (a) Representative local field potent
during whisker stimulation. Traces in front of light grey background were
background represents an animal with bilateral common carotid artery occ
(each is the mean of four stimulations in an animal representative of each
amplitude of the CBF response to whisker stimulation. The base of each b
stimulation. In (b) and (d), data are given as mean ± stdev; sample size (i.e.
analysis relied on a two‐way ANOVA paradigm (factors: ischaemia and tre
Howell post hoc test was applied for group comparisons (*P < 0.05 vs. veinduction with respect to the pretreatment CBF level (Figure 3a).
Further, nimodipine counteracted the reduction in CBF evoked by
2VO (Figure 3b) and prevented the development of post‐SD
oligaemia (Figure 3c).3.2 | Somatonsensory stimulation
For the estimation of drug effect on physiological neurovascular cou-
pling, somatosensory EFPs and the associated CBF response provoked
by whisker stimulation were evaluated in the somatosensory barrel
cortex in Series 2 (Figure 4). The amplitude of EFPs was considerablyvoked potentials and the coupled cerebral blood flow (CBF) response
ial (LFP) traces display somatosensory evoked field potentials (EFPs)
taken from intact animals, while the trace in front of dark grey
lusion (2VO). (b) The peak amplitude of evoked potentials. (c) Traces
condition) show the CBF response to whisker stimulation. (d) The
ar in the chart is set to the CBF level directly preceding whisker
, the number of events analysed) is indicated in each bar. Statistical
atment). The level of significance was defined as *P < 0.05. A Games–
hicle; #P < 0.05 vs. LA1011; $P < 0.05 vs. respective intact)
1228 SZABÓ ET AL.BJPattenuated during ischaemia (in the presence of 2VO) with respect to
the intact condition (Figure 4b). The application of LA1011 exerted no
effect on EFPs; however, nimodipine dramatically decreased the
amplitude of evoked potentials in the intact cortex (Figure 4a,b). The
relative amplitude of the hyperaemic response was notably smaller
during ischaemia (2VO) than in the intact brain (Figure 4c,d). Treat-
ment with LA1011 did not improve functional hyperaemia signifi-
cantly, but nimodipine restored the relative amplitude of the CBF
response to the intact level (Figure 4d). In addition to the elevation
of baseline CBF achieved by nimodipine, the further improvement in
the CBF response to whisker stimulation in the ischaemic cortex was
very apparent (Figure 4d).3.3 | Spreading depolarization
Experimentally‐evoked SDs were exploited for the investigation of
drug effect on non‐physiological neural depolarization and the associ-
ated CBF response (Figures 5 and 6). The SD1 was taken apart from
rSD events for analysis, because of known dissimilarities between
SD1 and rSDs (Farkas, Pratt, Sengpiel, & Obrenovitch, 2008). Eventu-
ally, detailed data analysis was completed on rSDs. As expected, the
amplitude of SD events was not altered (Series 2), while their duration
was extended (Series 2) during ischaemia with respect to the intact
condition (Figure 5a–c). Chronic or acute application of LA1011 con-
sistently intensified SD amplitude, irrespective of ischaemia (Series 2;
Figure 5b). In contrast, acutely applied nimodipine significantly
decreased SD amplitude (Series 2). In addition, nimodipine shortened
SD duration in the ischaemic cortex to its intact level (Series 2;
Figure 5c).
The CBF response to SD consists of four elements, starting
with a transient hypoperfusion, followed by a peak and then a late
hyperaemia, and concluded by a long‐lasting oligaemia (Ayata &Lauritzen, 2015). The share of the individual elements in the CBF
response to SD is variable across animal species and anaesthesia
protocols and appears to change markedly according to the actual
metabolic status of the tissue (Ayata & Lauritzen, 2015).
The analysis of the CBF response here predominantly focused on
the hyperaemia phase. The kinetics of the observed CBF responses
exhibited a spectrum considering the weight of late hyperaemia in
the signature (Figure 6a). Further, the presence of the late hyperaemic
element served as the basis for CBF response classification to distin-
guish CBF response Type 1 characterized by peak hyperaemia only,
from CBF response Type 2 that included late hyperaemia in addition
to the peak hyperaemia (Figure 6a). A semi‐quantitative approach of
ours indicated that the likelihood for Type 1 and Type 2 CBF
responses to evolve was near equal in the vehicle‐treated, intact
condition. Conversely, ischaemia, or treatment with LA1011 or
nimodipine, allowed late hyperaemia to emerge at a clearly higher
incidence (Figure 6b). The amplitude of peak hyperaemia was con-
served over experimental groups, except for nimodipine treatment in
the ischaemic condition, which augmented peak hyperaemia ampli-
tude ( Figure 6c). The duration of hyperaemia (i.e., peak and late
hyperaemia together) was not significantly altered by ischaemia or
the treatments (Series 2; Figure 6d).4 | DISCUSSION
The presented work investigated the potential neuroprotective
effect of LA1011, an Hsp27 and Hsp70 co‐inducer dihydropyridine
derivative with no affinity for L‐type voltage‐gated calcium channels
(Kasza et al., 2016), with reference to nimodipine, a well‐known
dihydropyridine compound that blocks L‐type voltage‐gated calcium
channels (Scriabine et al., 1989). In the incomplete global forebrain
ischaemia model used, we first assessed drug effect on physiologicalFIGURE 5 The impact of ischaemia or
pharmacological treatments on recurrent
spreading depolarization (rSD). (a) Traces
(each is the mean of rSDs in an animal
representative of each condition) demonstrate
the negative DC potential shift indicative of
rSDs, triggered after the bilateral occlusion of
the common carotid arteries (2VO). (b)
Amplitude of the negative DC potential shift
with rSDs. (c) Duration of the negative DC
potential shift with rSDs. (d) Rate of
repolarization of the negative DC potential
shift with rSDs. In (b) to (d), data are given as
mean ± stdev; sample size (i.e., the number of
events analysed) is indicated in each bar.
Statistical analysis relied on a three‐way
ANOVA paradigm (factors: acute/chronic,
ischaemia, and treatment). The level of
significance was defined as *P < 0.05. Tukey's
HSD (b) or a Games–Howell (c) post hoc test
was applied for group comparisons (*P < 0.05
vs. vehicle; #P < 0.05 vs. LA1011)
FIGURE 6 The impact of ischaemia or pharmacological treatments on the cerebral blood flow (CBF) response to recurrent spreading
depolarization (rSD) events. (a) Representative traces demonstrate the spectrum of the kinetics of the CBF response considering the weight of
late hyperaemia in the signature. The CBF response was classified as Type 1 whenever peak hyperaemia was obvious, with late hyperaemia being
undetectable. The CBF response was labelled Type 2, when both peak and late hyperaemia could be identified. (b) Occurrence of Type 1 and Type
2 CBF responses is depicted with respect to all of the CBF responses analysed being taken as 100% in each experimental group. Horizontal bars
with black outline (left) depict the share of Type 1, while bars with grey outline (right) represent the ratio of Type 2 CBF responses. Note that the
two types were represented equally (i.e., near 50% indicated by a vertical white band) in the vehicle‐treated, intact groups. In the animals
undergoing bilateral common carotid artery occlusion (2VO) and receiving LA1011 treatment, only Type 2 CBF responses were observed. Pearson
chi‐square test for association indicated a significant effect (value: 16.996, P < 0.017). Calculating column proportion by z test with Bonferroni
correction identified a significant shift inType 1 and Type 2 ratios for groups labelled (*). (c) Amplitude of peak hyperaemia. The base of each bar in
the chart is set to the CBF level preceding rSD events. (d) Duration of hyperaemia, that is, ΔT in Panel (a). In (b) to (d), data are given as
mean ± stdev; sample size (i.e., the number of events analysed) is indicated in each bar. Statistical analysis relied on a three‐way ANOVA paradigm
(factors: acute/chronic, ischaemia, and treatment). The level of significance was defined as *P < 0.05. Tukey's HSD test was applied for group
comparisons (*P < 0.05 vs. vehicle; #P < 0.05 vs. LA1011)
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the coupled functional hyperaemic response. Next, we focused on
the impact of the pharmacological treatments on SD and the associ-
ated CBF response. SD is an ischaemic preconditioning stimulus when
triggered in intact tissue (Shen et al., 2016) and represents a patho-
physiological process as it occurs due to extracellular potassium
and glutamate accumulation in ischaemic brain injury (Dreier, 2011;
Pietrobon & Moskowitz, 2014).
The cerebral ischaemia model has been selected to test the neuro-
protective efficacy of LA1011, because the drug has been shown to
co‐induce Hsp27 and Hsp70 (Kasza et al., 2016), both recognized to
mediate anti‐inflammatory and anti‐apoptotic mechanisms in ischae-
mic brain injury (Franklin, Krueger‐Naug, Clarke, Arrigo, & Currie,
2005; Nowak & Jacewicz, 1994; van der Weerd et al., 2010; Yenari
et al., 2005). The dose of the drugs applied in the present study was
justified by previous experimental results and our pilot experiments
(Kasza et al., 2016; Richter et al., 2002).
Here, we show in the anaesthetized rat that baseline CBF
remained unchanged after LA1011 administration but was increased
by nimodipine, as expected. Cerebrovascular smooth muscle cells are
enriched by L‐type voltage‐gated calcium channels. Nimodipine
inhibits calcium influx through these channels, leading to thehyperpolarization and relaxation of smooth muscle cells, and the
reduction of vascular tone (Scriabine & van den Kerckhoff, 1988).
The current data demonstrate that LA1011 does not alter neuronal
excitability in the intact cortex, which is consistent with the view that
LA1011 increases Hsp expression only under stress conditions (Kasza
et al., 2016). Further, LA1011 treatment did not restore EFP amplitude
compromised by ischaemia and did not improve the hyperaemic
response impaired by ischaemia, either. These results indicate that
acutely administered LA1011 does not protect neuronal excitability
or neurovascular coupling during the early phase of cerebral ischae-
mia. On the other hand, it is a novel finding of the presented work,
that, in addition to baseline CBF elevation, nimodipine profoundly
augmented functional hyperaemia in response to somatosensory stim-
ulation (Figure 3c,d), without enhancing EFP amplitude under ischae-
mia. Still, nimodipine remarkably decreased EFP amplitude in the
intact cortex, while the relative magnitude of the flow response
was maintained. Both observations imply that the enhancement of
functional hyperaemia by nimodipine is disproportionate with
respect to EFP amplitude. This suggests that nimodipine augmented
the amplitude of the CBF response (irrespective of the intensity
of neuronal activation initiated by somatosensory stimulation),
possibly by potentiating the release of vasodilator substances or the
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and epoxyeicosatrienoic acids are produced by astrocytes during
neurovascular coupling (Attwell et al., 2010), and L‐type voltage‐gated
calcium channels are present in the astrocyte plasma membrane
(Cheli et al., 2016), astrocytes may be involved in the nimodipine‐
related enlargement of functional hyperaemia, without neuronal con-
tribution being proportionally increased in the first place. Further
details concerning this suggestion are given as Supporting Information
to the paper.
Even though LA1011 treatment did not achieve a detectable
change in neuronal activity with somatosensory stimulation in our
experiments, it greatly enhanced the amplitude of SD, consistent in
all experimental conditions created. The amplitude of SD appears to
be fairly conserved, since neither ischaemia nor age can alter the
SD‐related DC potential amplitude (Menyhárt et al., 2015; Menyhárt
et al., 2017). However, several pharmacological manipulations have
proven to reduce the amplitude of SD. As such, topical application
of the pro‐inflammatory cytokine TNF‐α, the inhibition of the
P2X7/pannexin 1 pore by the drug A438079, the blockade of large‐
conductance Ca2+‐activated potassium channels by paxilline, or the
uncoupling of postsynaptic density protein 95 from NMDA receptors
by UCCB01‐144 (Tat‐N‐dimer) were all found to reduce the amplitude
of SD; TNF‐α, and A438079 even in a dose‐dependent manner (Chen
et al., 2017; Kucharz, Søndergaard Rasmussen, Bach, Strømgaard, &
Lauritzen, 2017; Menyhárt et al., 2018; Richter et al., 2014). Two of
these studies have pointed out that the amplitude of SD stands in a
strong, positive correlation with the extracellular concentration of
potassium (Chen et al., 2017; Menyhárt et al., 2018), which would
infer that treatment with LA1011, an Hsp co‐inducer, may support
cellular (possibly neuronal) potassium efflux with SD. Indeed, heat
shock preconditioning preserved the diminishing potassium peak
of recurrent depolarizations triggered by intermittent anoxia, and
Hsp70 expression modulated potassium homeostasis throughout
oxygen withdrawal in the drosophila brain (Armstrong et al., 2011).
Although it remains to be determined which potassium channels
may be tuned by Hsp70 in the mammalian nervous system, the
chaperon has been shown to activate potassium channels linked to
the rise of intracellular calcium near the plasma membrane in cultured
human promonocytes (Negulyaev, Vedernikova, Kinev, & Voronin,
1996) and to be involved in the assembly of specific voltage‐gated
potassium channels located in cardiac muscle (Ficker, Dennis, Wang,
& Brown, 2003).
As listed above, TNF‐α is also known to reduce the amplitude of
SD in a dose‐dependent manner (Richter et al., 2014). Interestingly,
the overexpression of Hsp70—a target of LA1011—was shown to sup-
press pro‐inflammatory cytokine mRNA levels, including TNF‐α in cul-
tured, oxygen–glucose‐deprived astrocytes (Kim, Yenari, & Lee, 2015).
Furthermore, up‐regulation of Hsp70 decreased TNF‐α expression
and improved neurological outcome in a rodent model of intracerebral
haemorrhage (Manaenko et al., 2010). On the basis of these observa-
tions, it would be attractive to postulate that LA1011 increased SD
amplitude possibly by the co‐induction of Hsp70 to cause the down‐
regulation of TNF‐α, which would normally limit the magnitude ofSD. The mechanistic link between LA1011 treatment and SD remains,
however, speculative, and the temporal profile of Hsp induction in the
model used is also obscure. Therefore, further investigations are
needed to explore the LA1011‐related signalling that causes increas-
ing SD amplitude.
In contrast to LA1011, nimodipine application reduced SD size,
in agreement with previous reports applying nimodipine at the con-
centration used here (Menyhárt et al., 2018; Richter et al., 2002).
Neurons express L‐type voltage‐gated calcium channels, which have
been implicated in the modification of neuronal excitability, and are
a well‐known target of nimodipine (Scriabine et al., 1989). Taken
together, the opposite actions of LA1011 and nimodipine on SD
amplitude correspond reliably to the different cellular targets of the
two molecules.
Although pharmacologically decreased SD amplitude is often
interpreted as a sign of protection (Richter et al., 2014), the lack of a
clear‐cut association between SD amplitude and histological or neuro-
logical damage imposed creates persistent controversies. On the other
hand, the number of rSDs, the cumulative duration of SDs, and the
inability of the tissue to recover from SD (i.e., long SD duration) have
been shown to correlate with or be a sign of injury progression
(Dijkhuizen et al., 1999; Dreier et al., 2006; Nedergaard, 1996). In this
context, LA1011 proved to be ineffective, since SD duration was not
altered under LA1011 treatment (Figure 4c). Nimodipine, however,
showed a tendency to shorten SD duration (Figure 4c), which may
be accepted as a sign of its protective potential. SD is associated with
neuronal calcium loading, in part via ionotropic glutamate receptors,
such as the NMDA receptor (Pietrobon & Moskowitz, 2014). The
reduction of the SD‐associated calcium influx has thus emerged as a
promising target to achieve SD inhibition. For example, low‐dose
ketamine (an NMDA receptor blocker) applied to brain slices has
recently been shown to reduce calcium load and to facilitate the
recovery from SD (Reinhart & Shuttleworth, 2018). In our study,
nimodipine is thought to have inhibited calcium influx to neurons via
L‐type voltage‐gated calcium channels, which also caused the more
rapid recovery from SD. Together, these results suggest that the atten-
uation of neuronal calcium load (either via NMDA receptor blockade or
via L‐type calcium channel inhibition) shortens SD duration.
Before the detailed discussion of drug effects, it must be appre-
ciated that hyperaemia in response to SD was markedly accentuated
under α‐chloralose anaesthesia used here (relative amplitude:
191 ± 61 and 151 ± 96%, intact and under ischaemia, respectively),
with respect to that seen under isoflurane anaesthesia in our previ-
ous work (e.g., 51 ± 38 and 21 ± 11%, intact and under ischaemia,
respectively, Varga et al., 2016; 76 ± 12 and 21 ± 9%, intact and
under ischaemia, respectively, Menyhárt et al., 2017). Moreover, late
hyperaemia in the CBF response to SD was revealed very often
under α‐chloralose anaesthesia as seen here (Figures 2 and 6),
while it was seldom encountered in many of our previous studies
using isoflurane (Menyhárt et al., 2015; Menyhárt et al., 2017;
Varga et al., 2016). Finally, the global ischaemia model we routinely
use produces a considerable drop of CBF following 2VO under
isoflurane anaesthesia (e.g., to 27 ± 13%, Varga et al., 2016, to
SZABÓ ET AL. 1231BJP41 ± 9%; Menyhárt et al., 2015)—this drop proved to be considerably
more moderate under α‐chloralose anaesthesia here (Figure 3b).
Therefore, we propose that the anaesthetic procedure used in this
study allowed the frequent evolution of large hyperaemia in response
to SD, also when SD was elicited after the occlusion of the common
carotid arteries.
The experiments presented here show that the kinetics of
SD‐related hyperaemia was transformed discernibly by ischaemia
and LA1011 or nimodipine treatment. In other words, the experimen-
tal manipulations accentuated the element of late hyperaemia in the
SD‐associated CBF response (Figure 5a,b). On the basis of an original
finding that L‐arginine administration supported late hyperaemia fol-
lowing SD (Fabricius, Akgoren, & Lauritzen, 1995), late hyperaemia
was proposed to be NO dependent (Ayata & Lauritzen, 2015). Since
baseline CBF elevation by L‐arginine can be linked to increased endo-
thelial NOS (eNOS) activity (Yamada et al., 2000), and ischaemia
apparently potentiates eNOS expression (Bolaños & Almeida, 1999),
it is conceivable that the increased share of late hyperaemia in the
CBF response to SD was supported by increased eNOS activity in
our ischaemic condition. Interestingly, Hsps, particularly Hsp90, have
been implicated in the adjustment of vascular tone via modulating
the production of the vasodilator NO (García‐Cardeña et al., 1998),
and a recent report has shown LA1011 to bind Hsp90 and activate
the ATPase activity of Hsp90 (Roe et al., 2018). A potential interaction
between LA1011 and NO release to unravel late hyperaemia in the
SD‐related CBF response may thus be mediated via Hsp90; however,
the signalling cascade remains hypothetical due to the paucity of
explicit experimental data.
In conclusion, the current study appears to confirm the Hsp co‐
inducer and possibly anti‐inflammatory potential of LA1011 during
stress to the nervous tissue. Furthermore, the work demonstrates that
L‐type voltage‐gated calcium channel inhibition augments functional
hyperaemia in response to somatosensory stimulation especially under
ischaemia, in addition to achieving a general, constitutive vasodilator
effect. A more detailed understanding of the molecular pathways
involved either in LA1011 or in nimodipine action assessed here
requires further investigation. Overall, previous data (Kasza et al.,
2016; Penke et al., 2018; Roe et al., 2018) and those of ours together
suggest that LA1011 may be considered to counteract neurodegener-
ation, with no major, concomitant impact on vascular tone or
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